Heatwurx (NASDAQ:PCSA) Announces Quarterly Earnings Results, Misses Expectations By $60.58 EPS

Heatwurx (NASDAQ:PCSA) announced its quarterly earnings data on Friday. The company reported ($61.58) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($60.58), FiscalAI reports.

Heatwurx Stock Performance

Shares of Heatwurx stock traded up $0.02 during trading hours on Friday, reaching $1.86. The company’s stock had a trading volume of 18,724 shares, compared to its average volume of 121,503. Heatwurx has a one year low of $1.04 and a one year high of $8.88. The company’s 50 day simple moving average is $1.81 and its 200 day simple moving average is $2.30. The stock has a market cap of $5.21 million, a P/E ratio of -0.44 and a beta of 1.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Heatwurx presently has a consensus rating of “Sell”.

About Heatwurx

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.